



Contact

John R. Ingrassia

Partner

Washington, DC +1.202.416.6869

jingrassia@proskauer.com

John advises on the full range of foreign investment and antitrust matters across industries, including chemicals, pharmaceutical, medical devices, telecommunications, financial services consumer goods and health care. Clients turn to John for matters related to competition and antitrust, CFIUS, or foreign investment issues.

For more than 25 years, John has counselled businesses, private equity and venture firms facing the most challenging antitrust issues, helping them avoid regulatory issues in areas such as distribution, pricing, channel management, mergers, acquisitions, joint ventures and price gouging compliance.

John's practice specializes in analyzing and resolving CFIUS and antitrust issues related to mergers, acquisitions, and joint ventures, as well as assessing pre-merger CFIUS and HSR notification requirements. He provides guidance to clients on CFIUS national security reviews and assists with CFIUS submissions when non-U.S. buyers aim to acquire U.S. businesses with national security concerns. He also regularly advises clients on international antitrust issues in proposed acquisitions and joint ventures, including reportability under the EC Merger Regulation and numerous other foreign merger control regimes.

His knowledge, reputation and extensive experience with the legal, practical, and technical requirements of merger clearance make him a recognized authority on Hart-Scott-Rodino antitrust merger reviews. John is regularly invited to participate in Federal Trade Commission and bar association meetings and takes on the issues of the day.

Matters

Representative Matters:

- ? [P](#) resonant Inc. in the sale of the company to Murata Electronics for \$295.7M
- ? [M](#) o-Sci Corporation, a world leader in the supply of medical and specialty glass, and ETS Technology Holdings LLC, a provider of wound care technologies, in the sale of the companies to The Heraeus Group
- ? [F](#) TC/antitrust clearance for Arkema's acquisition of the Ashland adhesives business
- ? [C](#) hurch & Dwight in its \$630 Million Acquisition of the Hero Mighty Patch Brand
- ? [G](#) rifols and Biomat in \$1 Billion Strategic Investment by GIC
- ? [G](#) rifols in \$1.9 Billion Strategic Alliance with Shanghai RAAS to Boost the Growth of its Plasma Derived Products and Diagnostic Solutions in China
- ? [K](#) B Foods in its bankruptcy divestiture of Balducci's and King Foods stores to Albertsons
- ? [C](#) hurch & Dwight in its \$580 Million Agreement to Acquire TheraBreath
- ? [C](#) hurch & Dwight in its acquisition of Zicam Brand for \$530 Million
- ? [O](#) ssur Hf's in its acquisition of College Park Industries, Inc.
- ? [H](#) enry Schein in its spin-off and merger of its animal health business with Vets First Choice, creating Covetrus -- a global animal-health company dedicated to empowering veterinary practices

Practices

Antitrust, Antitrust Technology Task Force, Mergers & Acquisitions, Secondary Transactions and Liquidity Solutions, Private Equity Transactions

Industries

Asset Management, Private Capital, Private Equity

Education

Hofstra University School of Law, J.D.

Pace University, B.A.

Admissions & Qualifications

New York

District of Columbia

Court Admissions

U.S. Court of Appeals, Fourth Circuit

District of Columbia Court of Appeals

Supreme Court of New York, Appellate Term

Memberships

Chair of the Kentlands Citizens Assembly

Council for Court Excellence Board Member; co-Chair, Justice of Education Committee

District of Columbia Bar, co-Chair, Antitrust and Consumer Law Section

District of Columbia Bar Nominations Committee

Legal Advisory Committee of the Cair Coalition

Awards & Recognition

Legal 500 US Antitrust: Civil Litigation/Class Actions: Defense, 2023-2025

JD Supra Readers' Choice #1 Antitrust & Trade Regulation 2022

Washington DC Super Lawyers 2019